Gujarat Themis Biosyn has signed asset purchase agreement to acquire a portfolio of anti-tuberculosis (TB) and anti-infective brands from Sanofi, the French-holding company of the Sanofi group, headquartered in Paris. The company now looks forward to working with Sanofi to ensure a seamless transition and continuity of supply to patients globally.

The acquisition, which remains subject to obtaining antitrust and foreign direct investment approvals in applicable jurisdictions, would involve 13 established branded generic products with a strong presence across more than 55 countries in Europe, the Middle East and Africa. The concerned portfolio reported net sales of around 62 million euro for the year ended 2025. The acquisition would include marketing authorizations, brands, regulatory dossiers, and inventory and associated commercial rights. The transaction does not involve the transfer of manufacturing facilities or employees, making it a capital-efficient and asset light expansion for the company.

This move would represent a significant step in the company’s strategy to strengthen its global pharmaceuticals platform and expand its presence in the anti-infective segment. The transaction would provide immediate access to regulated and semi-regulated markets, enabling the company to enhance its international footprint. The consideration for the transaction would be 158 million euro, payable in cash at closing and is expected to be funded by an optimal mix of debt and equity. The transaction is expected to close by the end of Q3FY27 (Quarter Ending December 31, 2026).

Gujarat Themis Biosyn is a biotech and synthetic product manufacturing company.